TECENTRIQ (atezolizumab) for Urothelial Carcinoma - Cancer Therapy Advisor

TECENTRIQ (atezolizumab) for Urothelial Carcinoma

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for TECENTRIQ (atezolizumab), indicated for urothelial carcinoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 9: Use in Specific Populations
Slide 12: Clinical Pharmacology
Slide 16: Warnings and Precautions
Slide 22: Clinical Safety and Efficacy
Slide 28: Drug Storage and Supply
Slide 30: References